drugset

drugset / Trial / NCT03437785

Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet

NCT03437785 ↗

Phase 2 Completed 250 enrolled Chong Kun Dang Pharmaceutical

RandomizedParallel-groupDouble-blindTreatment

Summary

To Evaluate the Efficacy and Safety of CKD-495

Timeline

Start: 2018-01-16
Primary completion: 2018-10-12
Completion: 2018-10-12

Publications

Park SH, Lee OY, Lee YC, Park KS, Park JJ, Park MI, Song GA, Lee DH, Jung H, Kim SK, Kim TN, Choi SC, Jee SR, Rew JS, Lee ST, Choi EK, Baik GH, Park SJ. A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis. Can J Gastroenterol Hepatol. 2025 Apr 10;2025:2702089. doi: 10.1155/cjgh/2702089. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Artemisiae argyi folium 95% ethanol ext.(20→1)	Unknown	60 mg	—
Subject	CKD-495	Unknown	75 mg	—
Subject	CKD-495	Unknown	150 mg	—
Comparator	Rebamipide	Small molecule	100 mg	—

Indications